Axis Securities Pure Contra PMS Review: Alpha, Fees & Portfolio Fit Decoded
| What Works | What Doesn’t |
| Exceptional long-run track record — 19.36% annualised since inception, beating the benchmark by 3.70% per year Strong 3-year and 5-year alpha (+3.22% and +4.48% annualised) — among the best in the Multicap PMS category Outstanding calendar year performance: 37.3% in CY21, 38.5% in CY23, and 29.4% in CY24 | 1-year return is deeply negative (-3.99%) while the benchmark held roughly flat (-0.07%) — a painful -3.92% gap 2-year return is also negative (-0.07%) against a benchmark that returned +4.14% — cumulative gap of -4.21% CY 2025 YTD figure (-3.4%) sharply trailed the benchmark (+7.6%) — a significant reversal from the strong CY24 |
The verdict: The Axis Securities Pure Contra PMS has one of the most credible long-term track records in the Multicap PMS space — but it has hit a wall in the last 24 months.
A strategy that compounded at 19.36% since inception is now sitting on a negative 1-year return while the benchmark is flat.
That tension — between a genuinely strong process and a genuinely difficult recent stretch — is what this review will help you think through, clearly and honestly.
Before diving into the data, here is the test every PMS must pass to justify its place in your portfolio:
| Gross Alpha > Fee | = Value Added |
| Gross Alpha ≈ Fee | = Break-Even |
| Gross Alpha < Fee | = Value Destroyed |
So where does the Axis Securities Pure Contra PMS sit today?
The answer is deliberately uncomfortable to state cleanly: on a 3-year and 5-year basis, it sits in the value-added zone — the alpha has meaningfully exceeded the 2.50% fixed fee.
On a 1-year and 2-year basis, it sits squarely in the value-destroyed zone — the strategy has underperformed its benchmark before fees are even considered. Both are true simultaneously.
That is not a contradiction — it is the central tension this article exists to resolve for you.
This review is written specifically for you if:
Here are the key facts about the strategy:
| Strategy Name | Axis Securities Pure Contra PMS |
| AMC | Axis Securities Ltd |
| Inception Date | 27 November 2020 |
| Category | Multi Cap & Flexi Cap |
| Benchmark | S&P BSE 500 TRI |
| AUM | Approx. ₹1,784 crores |
| Fund Manager | Mr. Nishit Master (Portfolio Manager, ~18+ years experience) |
| Minimum Investment | ₹50,00,000 |
| No. of Stocks | 31 constituents |
| Market Cap Composition | Large Cap 47.61% | Mid Cap 6.05% | Small Cap 36.44% | Cash 9.90% |
| Investment Approach | Three primary styles: Value investing (stocks available at discount to intrinsic value), Momentum-Alpha, and Special Situations. Value and Alpha-Momentum form the core; Special Situations is the satellite factor. |
| Fee Structure | Fixed: 2.50% p.a. OR Variable: 1.50% p.a. + 20% profit sharing above 2.50% quarterly hurdle |
| Exit Load | 3% (Yr1) | 2% (Yr2) | 1% (Yr3) | 0% thereafter |
The honest framing: this is a genuinely differentiated mandate.
The combination of value, momentum-alpha, and special situations is not what a standard flexi-cap mutual fund does — and the 31-stock portfolio with 36% in small caps is structurally distinct from the large-cap-heavy portfolios that dominate the PMS space.
The question is not whether the strategy is distinctive. It clearly is.
The question is whether the recent 24-month stretch of negative alpha is a temporary friction within a sound process, or a sign that the strategy’s edge has temporarily — or structurally — faded.
When did you last look at the full trailing return picture — not the since-inception headline, but every period, with the benchmark gap calculated explicitly?
Here it is:
| Period | Pure Contra | S&P BSE 500 TRI | Alpha (+/-) |
| 1 Month | 1.23% | -0.17% | +1.40% |
| 3 Months | 0.76% | -2.34% | +3.10% |
| 6 Months | -2.68% | -5.39% | +2.71% |
| 1 Year | -3.99% | -0.07% | -3.92% |
| 2 Year | -0.07% | 4.14% | -4.21% |
| 3 Year | 16.68% | 13.46% | +3.22% |
| 5 Year | 16.77% | 12.29% | +4.48% |
| Since Inception | 19.36% | 15.66% | +3.70% |
Returns over 1 year are annualised; returns of 1 year or less are absolute. TWRR basis, net of all fees and charges. As on 31st May 2026.
| Year | Pure Contra | BSE 500 TR | Assessment |
| CY 2021* | 37.3% | 31.6% | Clear outperformance |
| CY 2022 | 9.7% | 4.8% | Clear outperformance |
| CY 2023 | 38.5% | 26.5% | Exceptional outperformance |
| CY 2024 | 29.4% | 15.8% | Strong outperformance |
| CY 2025 YTD | -3.4% | 7.6% | Sharp underperformance |
*Effective 1 Jan 2021. Source: Axis Securities factsheet as on 31st December 2025.
Here is the thing. The calendar year table tells a remarkably clear story.
From inception through CY 2024, this strategy beat the benchmark every single year — and not by a small margin.
The CY 2023 and CY 2024 numbers (38.5% and 29.4% against benchmark returns of 26.5% and 15.8%) are the kind of performance that builds conviction.
Then CY 2025 happened. The strategy posted -3.4% against a benchmark return of +7.6% — a gap of more than 11 percentage points in a single year. That is not a rounding error.
That is a style dislocation. A contra and value-biased strategy that deliberately buys unloved stocks at depressed valuations will, by construction, lag during periods when the market rewards quality momentum and large-cap defensives — and 2025 was precisely that kind of market.
But context is not absolution. Four consecutive years of outperformance followed by a significant reversal raises a legitimate question: was CY 2025 an extreme but temporary style headwind that the process will recover from, or does it signal that the portfolio had run ahead of itself after four very strong years and is now mean-reverting?
Neither answer is certain. Both are worth sitting with honestly.
If the index is doing more with less right now, what exactly are you paying 2.50% annually for?
The Axis Securities Pure Contra fee structure is straightforward: a fixed management fee of 2.50% per annum charged quarterly.
There is also a variable option: 1.50% p.a. plus 20% profit sharing above a 2.50% quarterly hurdle.
Either way, this is a meaningfully higher cost than a passive index fund.
Here is the rupee reality on ₹50 lakhs, using the strategy’s actual 5-year net trailing return compared against a low-cost index fund:
| Scenario | Net Return Assumed | Corpus After 5 Years | Corpus After 7 Years |
| Axis Securities Pure Contra (net, 16.77% p.a.) | 16.77% | ₹1,08,55,000 | ₹1,48,01,000 |
| Passive Index Fund (12.29% – 0.15% fee = ~12.14%) | 12.14% | ₹88,67,000 | ₹1,11,50,000 |
| The Advantage in PMS Favour | — | ₹19,88,000 | ₹36,51,000 |
Based on the strategy’s actual 5-year net trailing return (16.77%) versus the benchmark (12.29%), with an index fund fee assumption of 0.15%.
This is where the Axis Pure Contra story is genuinely different from most PMS reviews.
On a 5-year trailing basis, the strategy has delivered net returns that make the fee premium look well-justified — ₹19.88 lakhs more than a passive index fund on ₹50 lakhs over 5 years.
That is a real number, not a theoretical argument.
But here is the uncomfortable question that sits alongside that number: most of that outperformance was earned in CY 2021–2024.
The last 12 months have seen the strategy give back a meaningful chunk of that edge.
If the next 1-2 years look like CY 2025, does the 5-year advantage survive? You deserve to sit with that question rather than anchor only on the history.
Knowing everything you know today — the exceptional 4-year run, the sharp CY 2025 reversal, the negative 1-year and 2-year trailing returns, and the fees that continue regardless of which direction performance goes — if you were starting completely fresh with this money tomorrow, would you put it into this same product?
Not the product you signed up for when the trailing numbers were gleaming.
The product as it actually exists today — in the middle of its most difficult stretch since inception.
This question is deliberately uncomfortable. Most of us do not apply zero-based thinking to money already invested.
Once capital is deployed, it picks up emotional weight: the entry story, the relationship with the advisor, the CY23 statement that felt so good to read.
Behavioural economists call the pull of past investment history sunk cost bias — and it is one of the most well-documented reasons investors stay in underperforming positions longer than the data warrants.
But here is what that bias obscures: your money does not know how it got there.
It is just capital, sitting in a vehicle, earning whatever it earns — exactly as it would if you deployed it fresh tomorrow.
The history is irrelevant to the forward decision. Only the forward evidence matters.
In this case, the forward evidence is genuinely mixed. Four years of consistent outperformance followed by a single year of sharp underperformance could be a style dislocation that self-corrects — the strategy’s own history from CY 2022 (a year when contra and value worked brilliantly while momentum failed) supports that reading. Or it could signal a more persistent headwind.
What would you do with this money, knowing what you know?
If your honest answer is stay — because you have a long horizon, conviction in the process, and the stomach for another 12 months of possible underperformance — that is a reasoned decision.
Hold it with clarity, not inertia. If your honest answer is leave — because the 1-year and 2-year numbers have shaken your conviction and you are not sure the next 3 years look different from the last 2 — that is also a valid decision.
The failure would be staying without examining the question.
Twelve factors, scored honestly, with full analysis directly alongside each rating.
| Decision Factor | Rating | Analysis |
| Uniqueness vs existing MF portfolio | 🟢 | This is one of the clearer passes in the scorecard. A contra strategy with 36% in small caps, investing in beaten-down stocks, special situations, and discount valuations is structurally different from the flexi-cap and large-cap funds that dominate most HNI mutual fund portfolios. The top holdings — Indus Towers, Jio Financial Services, Thomas Cook, Motherson Sumi Wiring — are not the consensus growth names that populate most flexi-cap portfolios. That said, ICICI Bank, Mahindra & Mahindra, ITC, and Larsen & Toubro do appear in many broad-based mutual funds. The differentiation is real, but it is not 100%. A stock-level overlap check against your specific MF portfolio is still worth doing. |
| Alpha consistency across all periods | 🟡 | The pattern here is striking and important. On every trailing period from 3 years outward — including since inception — this strategy has generated positive alpha. On the 1-year and 2-year windows, it has generated sharply negative alpha (-3.92% and -4.21% respectively). The calendar year data makes the story even clearer: four consecutive years of outperformance (CY21-CY24), then a sharp reversal in CY 2025 YTD (-3.4% vs +7.6%). This is not diffuse, persistent underperformance — it is a concentrated dislocation concentrated in the most recent period. That makes the style-cycle explanation more credible here than in strategies where underperformance is spread across multiple periods. |
| Justification for PMS premium fee | 🟡 | On a 5-year basis, the fee is clearly justified — 16.77% net versus 12.29% for the benchmark, compounding to a meaningful real rupee advantage. This is not a marginal case; the outperformance has been material enough to absorb the 2.50% annual fee and still deliver superior outcomes. On a 1-year and 2-year basis, the fee is clearly unjustified — you are paying 2.50% per year for a strategy that has returned -3.99% and -0.07% while the benchmark returned -0.07% and +4.14%. The fee is not contingent on performance; it leaves your account whether the market cooperates or not. |
| Downside protection in market corrections | 🟢 | The most recent 1-month, 3-month, and 6-month trailing periods have all shown the strategy cushioning losses relative to the benchmark — alpha of +1.40%, +3.10%, and +2.71% respectively during broadly negative market phases. This is exactly what a contra and value-biased strategy is built to deliver: asymmetric protection when the market falls. The formal risk metrics from the factsheet reinforce this: an up-capture ratio of 116 (the strategy participates more in rising markets) alongside a down-capture ratio of 100 (matching the market on down days) — with a higher Sharpe ratio (0.92) and Sortino ratio (0.92) than the benchmark. This risk-adjusted quality is a genuine positive. |
| Portfolio complement for MF investor | 🟢 | For an investor whose core is built around broad-based flexi-cap, index, or quality-oriented mutual funds, a dedicated contra strategy with meaningful small-cap exposure and a special situations sleeve does add a genuinely differentiated return stream. Contra styles tend to be cyclically uncorrelated with quality-growth styles — they underperform when momentum and growth outperform, and outperform when value and beaten-down names recover. The complement case is stronger here than for large-cap or generic Multicap strategies. Just check the specific stock-level overlap against your existing holdings before concluding the differentiation is complete. |
| Mandate purity and discipline | 🟢 | The strategy has remained consistently true to its stated approach: value-oriented, contra-tilted, willing to hold special situations and beaten-down names that the market dislikes. There is no evidence of momentum-chasing or style drift — in fact, the CY 2025 underperformance is itself evidence of mandate discipline, as the strategy held its contra positions while a momentum-driven market rewarded different styles. Discipline that costs you in the short term but preserves the process that generated long-term alpha is a positive, not a negative. The concern would be if the strategy had abandoned its style during the difficult stretch — and it has not. |
| Fund manager transparency | 🟢 | Nishit Master’s approach is well-documented and clearly articulated: a three-checkpoint framework covering promoter quality and wealth creation history for minority investors, free cash flow generation quality, and business scalability. The contra identification process is also clearly stated — recognising cycle turns while consensus remains negative, and spotting stocks that look expensive on earnings but cheap on balance sheet with early signs of earnings reversal. This level of process transparency is above average for the PMS industry. You know what you own and why. The fund manager’s communication — through media appearances, factsheets, and fund manager briefs — is regular and substantive. |
| Investment horizon suitability | 🟡 | On a 3-year or longer horizon, the data strongly supports the strategy — it has compounded at 16.68% against a benchmark of 13.46% over 3 years, and 16.77% versus 12.29% over 5 years. If you can hold for 3+ years without being derailed by short-term statement anxiety, the odds are in your favour based on the strategy’s own history. The concern is the 1-2 year window. If your effective decision-making horizon is 12-24 months — either because you need the liquidity, because you are evaluating performance annually, or because you find the exit load schedule constraining — the short-run data does not currently support the investment. |
| Market cap flexibility utilisation | 🟢 | This is one of the scorecard’s clearer greens. With 36.44% in small caps — nearly double the large-cap weight (47.61%) that dominates most Multicap PMS strategies — the portfolio is genuinely using its cross-cap mandate. The small-cap weighting is where special situations and contra names with the most meaningful valuation discounts often reside. This also explains some of the CY 2025 pain: small-cap stocks corrected significantly in the back half of 2025, and a portfolio with 36% in small caps would have felt that acutely. The flexibility is being actively used; the question is only whether the timing of that usage has recently worked against short-term returns. |
| Concentration vs diversification balance | 🟡 | 31 stocks with top-5 holdings at 33.19% and top-5 sectors at 64.62% is a moderately concentrated portfolio. The top-5 sector concentration is notably high and worth acknowledging: with 23.4% in financials and 14.6% each in automobiles and industrials, the portfolio has meaningful sectoral bets, not just stock-level conviction. This kind of concentration is appropriate — even necessary — for a strategy that is explicitly making contrarian sector bets. But it does mean that when those sector bets are wrong simultaneously (as they were in CY 2025), the drawdown can be sharper than a more diversified portfolio. The 36.44% small-cap weight amplifies this. This is not a flaw in the design — it is the design. Just make sure you knew this when you invested. |
| AUM size and strategy capacity | 🟡 | At approximately ₹1,784 crores, this is a moderate-sized PMS. For the large-cap portion of the portfolio, this AUM presents no constraints. For the 36.44% in small caps, however, ₹650+ crores chasing small-cap contra names does create a meaningful potential for impact on entry and exit — particularly for names like Thomas Cook India (market cap ₹8,120 crores) where even a 3-4% position represents a significant ownership stake. This is worth monitoring. The strategy’s small-cap edge depends in part on the ability to accumulate and exit positions without moving the market. As AUM grows, that edge can compress — a known challenge for all small-cap-leaning PMS strategies. |
| Manager tenure and continuity risk | 🟢 | Nishit Master has managed this specific strategy since its inception in November 2020 — nearly 5.5 years of continuous ownership of the process and outcomes. With 18+ years of experience across both buy-side and sell-side firms, his pedigree and track record at this specific strategy are well-documented and verifiable. Key-person risk exists — as it does with any concentrated-mandate PMS where the strategy is built around the specific judgment of one portfolio manager. But there is no recent evidence of team disruption or manager change. The person who built the track record is the person still managing the money. |
| Decision Factor | Rating | One-Line Take |
| Uniqueness vs existing MF portfolio | 🟢 | Genuinely differentiated — contra, small-cap, special situations |
| Alpha consistency across all periods | 🟡 | Strong 3Y/5Y/inception; sharply negative 1Y/2Y |
| Justification for PMS premium fee | 🟡 | Justified on 5Y history; not justified on 1Y/2Y recent data |
| Downside protection in corrections | 🟢 | Positive alpha in recent 1M, 3M, 6M — solid cushioning |
| Portfolio complement for MF investor | 🟢 | Adds contra/value/small-cap exposure most MF portfolios lack |
| Mandate purity and discipline | 🟢 | No style drift; CY25 pain is evidence of discipline, not failure |
| Fund manager transparency | 🟢 | Clear process, well-documented framework, regular communication |
| Investment horizon suitability | 🟡 | Works at 3Y+; data does not support 1-2 year window |
| Market cap flexibility utilisation | 🟢 | 36% small-cap — flexibility actively and genuinely used |
| Concentration vs diversification balance | 🟡 | 64.62% top-5 sectors — high conviction, not diversification |
| AUM size and strategy capacity | 🟡 | Manageable overall; small-cap sleeve bears watching |
| Manager tenure and continuity risk | 🟢 | Continuous since Nov 2020; same manager, same process |
Seven green, four ambers, zero red — the strongest scorecard of any strategy reviewed in this series so far. But the four ambers are not minor footnotes.
They sit at the most consequential decision points: alpha consistency, fee justification, horizon suitability, and sector concentration. If you are evaluating this on a 12-24-month window, those four ambers carry most of the weight.
Take a step back from this one PMS.
Is the Axis Securities Pure Contra strategy playing a satellite role in your portfolio — adding something genuinely distinct that your core cannot reach — or has it quietly become a parallel portfolio with overlapping names at a higher price?
The answer matters more than any trailing return number.
A contra strategy with 36% in small caps and a genuine special situations sleeve is, in principle, exactly the kind of satellite allocation that earns a PMS fee.
It accesses market segments that most mutual funds cannot efficiently reach, runs a process that most index and flexi-cap funds are structurally prohibited from replicating, and behaves differently across market cycles.
If your core is built on index funds, large-cap funds, and broad flexi-cap funds, this strategy genuinely adds something new.
If your core already includes a dedicated contra mutual fund, a small-cap fund, or other concentrated value-oriented strategies, the incremental diversification benefit narrows considerably — and the 2.50% annual fee starts looking like the only material difference between the two.
If your honest answer to the Zero-Based Thinking Test leans toward exit, here is what it actually costs and what you need to plan for.
The exit load schedule is one of the steepest in the PMS category: 3% in year 1, 2% in year 2, 1% in year 3, and 0% thereafter. On ₹50 lakhs, a year-2 exit costs you ₹1 lakh in exit load alone — before tax. This is not a reason to avoid exiting if the decision is sound, but it is a real cost that belongs in the calculation.
Unlike a mutual fund, a PMS holds securities directly in your demat account. Capital gains are calculated stock by stock — long-term gains (holding over 12 months) are taxed at 12.5% above the ₹1.25 lakh exemption, and short-term gains at 20%, per current Indian tax rules. With 36% in small caps and active portfolio management, there may be a meaningful portion of short-term positions depending on your specific account’s portfolio age.
Given the strategy’s recent recovery signs (positive alpha across the last 1, 3, and 6 months), an immediate exit driven purely by the 1-year number may not be the most rational timing. If you decide to exit, a staggered approach across 2-3 tranches allows you to manage capital gains tax across financial years and avoid liquidating at a single point-in-time. The decision to exit should rest on structural reasoning — horizon fit, overlap analysis, fee justification — not on short-term market sentiment.
As of the most recent disclosed period, the strategy has returned 1.23% over 1 month, 0.76% over 3 months, -2.68% over 6 months, -3.99% over 1 year, -0.07% over 2 years, 16.68% over 3 years, 16.77% over 5 years, and 19.36% annualised since its November 2020 inception. The benchmark (S&P BSE 500 TRI) returned -0.17%, -2.34%, -5.39%, -0.07%, 4.14%, 13.46%, 12.29%, and 15.66% over the same periods.
Yes, on the 1-year and 2-year trailing windows. On the 3-year, 5-year, and since-inception windows, it has generated consistent, meaningful positive alpha. The underperformance is concentrated in the CY 2025 period and reflects a style-cycle dislocation rather than persistent multi-year erosion.
The strategy offers two fee options: a fixed fee of 2.50% per annum charged quarterly, or a variable option of 1.50% p.a. plus 20% profit sharing above a 2.50% quarterly hurdle. Exit loads are 3% in year 1, 2% in year 2, and 1% in year 3, then zero thereafter.
Mr. Nishit Master is the Portfolio Manager with over 18 years of experience across buy-side and sell-side firms. He has managed this specific strategy since its inception in November 2020 and is well-known for clearly articulating his three-checkpoint investment framework: promoter quality, free cash flow generation, and business scalability.
The Axis Securities Pure Contra PMS strategy manages approximately ₹1,784 crores, making it a mid-sized PMS strategy. The AUM is appropriate for the large-cap portion of the portfolio; the small-cap sleeve (36% of assets) bears monitoring as AUM grows.
A contra or contrarian strategy deliberately invests in stocks that the market dislikes — beaten-down names trading at a discount to intrinsic value, or companies hit by temporary events that have temporarily impaired earnings. The thesis is that when consensus is overly negative, the price reflects excessive pessimism and the future return is asymmetric to the upside. By construction, contra strategies underperform when the market rewards consensus and momentum, and outperform when value recovers.
For investors whose core portfolio is built on index funds, flexi-cap funds, or quality-growth-oriented strategies, a contra PMS can add a genuinely differentiated, cyclically uncorrelated return stream. The complementarity breaks down if the investor already runs a dedicated contra mutual fund or small-cap fund — in that case, the incremental addition is limited and the fee premium is harder to justify.
The key structural differences are: PMS assets sit in your own demat account (tax is calculated per stock, not at the fund level), the minimum investment is ₹50 lakhs versus ₹500 for most mutual funds, the fee is 2.50% p.a. versus 0.5-1.5% for most active mutual funds, and the portfolio concentration (31 stocks with 36% in small caps) is tighter than a typical diversified mutual fund. The PMS format adds genuine value where the concentration and flexibility create alpha that a mutual fund structure cannot efficiently generate.
On submitting a withdrawal request, the portfolio manager liquidates your specific holdings from your Demat account and transfers proceeds after applicable exit loads and capital gains tax. The tax treatment is stock-by-stock — each position’s gain or loss is calculated individually based on your holding period and purchase price, not pooled at the fund level as with a mutual fund.
That depends entirely on your horizon, your portfolio context, and your conviction in the process. If you have a 3-year or longer horizon and the strategy genuinely complements rather than duplicates your existing mutual fund portfolio, the evidence supports staying invested. If your effective horizon is shorter, or if the strategy overlaps meaningfully with your existing holdings, the decision calculus shifts. The Zero-Based Thinking Test — would you invest this money fresh today — is the most useful filter.
At Holistic Financial Services, we evaluate PMS strategies across the market with one clear filter: does this strategy genuinely complement your existing portfolio, or does it simply replicate what your mutual funds already do?
We only recommend a PMS where it adds something structurally distinct — accessing market segments, styles, or opportunities that your core mutual fund holdings cannot.
If you would like us to assess whether your current PMS is truly earning its place — or to identify one that does — we offer a complimentary portfolio review consultation.
Just a conversation grounded in data, and a clear second opinion on whether every rupee is working as hard as it should.
Listen to this article Can the IndiaFirst Life Growth of Life Dreams Plus Plan truly…
Listen to this article Quick Summary Box What Works What Doesn't Genuine small-cap differentiation —…
Listen to this article Can the IndiaFirst Life Smart Retirement Plan help you build the…
Listen to this article Can the SBI Life Smart Platina Advantage Plan help you build…
Listen to this article Quick Summary Box What Works What Doesn't Genuine 16-year track record…
Listen to this article Quick Summary What Works What Doesn't Strong since-inception alpha (+4.89% annualised…